Association of Reproductive Health Professionals
Association of Reproductive Health Professionals
Reproductive Health Topics Publications & Resources Professional Education Newsroom Membership Policy & Advocacy About Us
ARHP Testimony
ARHP Applauds FDA Label Change for Mifepristone

April 1, 2016

Washington, DC

The Association of Reproductive Health Professionals applauds the US Food and Drug Administration's (FDA) recent approval of new labeling information for mifepristone, the medication abortion pill marketed in the US as Mifeprex. We join our colleagues at the American Medical Association, the American College of Obstetricians and Gynecologists, and many other professional and reproductive health and rights organizations in supporting this revision that reflects evidence-based practice. The new label lowers the recommended dosage of one of the two drugs used, extends the timeframe for when a woman can take the pill, and reduces the number of visits a woman must make to her provider.

ARHP supports the FDAs efforts to make changes that are safe and effective for patients while also demonstrating the importance of increased access to the full spectrum of reproductive health care, including abortion care. Under these new label guidelines, women will now be able to undergo medication abortion with fewer associated costs, side effects, and more convenience.

ARHP encourages states that have enacted laws based on old labeling to revise their laws according to the new prescription guidelines. This will help ensure women have access to this safe and legal medication abortion, regardless of their geographic location in the US.